1,399
Views
7
CrossRef citations to date
0
Altmetric
Oncology

Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States?

, , , , , , , & show all
Pages 152-162 | Received 14 Jul 2017, Accepted 14 Sep 2017, Published online: 17 Oct 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (6)

Megan Ellis Price, Sarah Gordon, Caroline Emmitt, Nambi Ndugga, Aigerim Kabdiyeva, Hillary Mull, Steven Pizer & Melissa M. Garrido. (2023) Growth of community‐based immunotherapy treatment in the Veterans Health Administration . Cancer Medicine.
Crossref
AM Boyd, C Sue, A Khandoobhai, B Vinson, H Shaikh, S Sorenson, V Patel, B Snyder, C Bondarenka, Y Koukounas, M Earl & M Jenkins. (2023) Evaluation of oncology infusion pharmacy practices: A nationwide survey. Journal of Oncology Pharmacy Practice, pages 107815522311703.
Crossref
Carolyn Kusoski, Jennifer Booth, Stephanie Salch, Harrison Jozefczyk & Julie Kennerly-Shah. (2021) Costs associated with United States pharmacopeia compliant infusion clinics. Journal of Oncology Pharmacy Practice 28:1, pages 141-148.
Crossref
Andrea Spini, Giulia Hyeraci, Claudia Bartolini, Sandra Donnini, Pietro Rosellini, Rosa Gini, Marina Ziche, Francesco Salvo & Giuseppe Roberto. (2021) Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data. International Journal of Environmental Research and Public Health 18:14, pages 7679.
Crossref
Ramin Rafiei, Chelsea Williams, Jeannette Jiang, Timothy Dy Aungst, Matthias Durrer, Dao Tran & Ralph Howald. (2021) Digital Health Integration Assessment and Maturity of the United States Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Autoinjectable Devices. JMIR mHealth and uHealth 9:3, pages e25406.
Crossref
Abhinav Vasudevan, Francis Ip, Danny Liew & Daniel R Van Langenberg. (2019) The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn’s Disease in the Biosimilar Era. Inflammatory Bowel Diseases.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.